2. Signaling Pathways
  3. Immunology/Inflammation
  4. PD-1/PD-L1
  5. PD-1/PD-L1 Antagonist

PD-1/PD-L1 Antagonist

PD-1/PD-L1 Antagonists (11):

Cat. No. Product Name Effect Purity
  • HY-P10439
    CVRARTR
    		Antagonist
    CVRARTR is a programmed cell death ligand-1 (PD-L1) antagonist with a KD of 281 nM. CVRARTR induces the internalization of PD-L1 and downregulates PD-L1 on the cell surface. CVRARTR restores cytokine secretion and T cell proliferation in cell CT26. CVRARTR exhibits antitumor efficacy against in CT26 homograft mouse model. CVRARTR can be used in melanoma research.
  • HY-P1812
    AUNP-12
    		Antagonist 99.31%
    AUNP-12 (NP-12) is a peptide antagonist of the PD-1 signaling pathway, displays equipotent antagonism toward PD-L1 and PD-L2 in rescue of lymphocyte proliferation and effector functions. AUNP-12 exhibits immune activation, excellent antitumor activity, and potential for better management of immune-related adverse events (irAEs).
  • HY-P1812A
    AUNP-12 TFA
    		Antagonist 98.03%
    AUNP-12 TFA (NP-12 TFA) is a peptide antagonist of the PD-1 signaling pathway, displays equipotent antagonism toward PD-L1 and PD-L2 in rescue of lymphocyte proliferation and effector functions. AUNP-12 TFA exhibits immune activation, excellent antitumor activity, and potential for better management of immune-related adverse events (irAEs).
  • HY-161748
    PD-1/PD-L1-IN-46
    		Antagonist
    PD-1/PD-L1-IN-46 (compound (R)-C27 ) is an PD-1/PD-L1 antagonist with IC50 value of 18.66 nM.
  • HY-P991357
    STT-001
    		Antagonist
    STT-001 is a human monoclonal antibody (mAb) targeting B7-H1/PD-L1/CD274. STT-001 can be used in Solid tumours research.
  • HY-P991354
    GR-1405
    		Antagonist
    GR-1405 is a human monoclonal antibody (mAb) targeting B7-H1/PD-L1/CD274. GR-1405 enhances cytotoxic T lymphocyte (CTL)-mediated antitumor immune responses against PD-L1-expressing tumor cells. GR-1405 can be used in Lymphoma and Solid tumours research.
  • HY-P991353
    Sym-021
    		Antagonist
    Sym-021 is a human monoclonal antibody (mAb) targeting PDCD1/PD-1/CD279. Sym-021 blocks the binding of PD-L1 and PD-L2 ligands, inducing the secretion of interferon IFN-γ and IL-2 and the proliferation of T cells. Sym-021 has anti-tumor activity in PDX mouse models.
  • HY-P991356
    FAZ-053
    		Antagonist
    FAZ-053 is a human monoclonal antibody (mAb) targeting B7-H1/PD-L1/CD274. FAZ-053 inhibits the interaction of PD-L1 with PD-1 and B7-1 on monocytes, dendritic cells, and B cells. FAZ-053 enhances interleukin 2 production. FAZ-053 can be used in advanced alveolar soft tissue sarcoma (ASPS), chordoma, and triple-negative breast cancer research.
  • HY-P991355
    PDL-GEX
    		Antagonist
    PDL-GEX is a human monoclonal antibody (mAb) targeting B7-H1/PD-L1/CD274. PDL-GEX can be used in cancer research.
  • HY-P991352
    SG-001
    		Antagonist
    SG-001 is a human monoclonal antibody (mAb) targeting PDCD1/PD-1/CD279. SG-001 can be used in Cervical cancer, Colorectal cancer, Solid tumours and Biliary cancer research.
  • HY-158052
    PD-1/PD-L1 antagonist 1
    		Antagonist
    PD-1/PD-L1 antagonist 1 (Compound A5) is an antagonist for programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1) interaction, with an IC50 of 23.78 nM.